CL2013002622A1 - Moleculas de union biespecificas que comprende al menos un componente que se une a dll4 y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. - Google Patents

Moleculas de union biespecificas que comprende al menos un componente que se une a dll4 y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.

Info

Publication number
CL2013002622A1
CL2013002622A1 CL2013002622A CL2013002622A CL2013002622A1 CL 2013002622 A1 CL2013002622 A1 CL 2013002622A1 CL 2013002622 A CL2013002622 A CL 2013002622A CL 2013002622 A CL2013002622 A CL 2013002622A CL 2013002622 A1 CL2013002622 A1 CL 2013002622A1
Authority
CL
Chile
Prior art keywords
molecule
nucleic acid
component
acid molecule
bispecific binding
Prior art date
Application number
CL2013002622A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Marie-Ange Buyse
Erick Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002622(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013002622A1 publication Critical patent/CL2013002622A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2013002622A 2011-04-01 2013-09-12 Moleculas de union biespecificas que comprende al menos un componente que se une a dll4 y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula. CL2013002622A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160920 2011-04-01

Publications (1)

Publication Number Publication Date
CL2013002622A1 true CL2013002622A1 (es) 2014-02-14

Family

ID=44314095

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002622A CL2013002622A1 (es) 2011-04-01 2013-09-12 Moleculas de union biespecificas que comprende al menos un componente que se une a dll4 y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.

Country Status (23)

Country Link
US (1) US20130078247A1 (enExample)
EP (1) EP2694545B1 (enExample)
JP (1) JP2014511682A (enExample)
KR (1) KR20140016345A (enExample)
CN (2) CN103596977B (enExample)
AP (1) AP2013007086A0 (enExample)
AR (1) AR085919A1 (enExample)
AU (1) AU2012234218A1 (enExample)
BR (1) BR112013025294A2 (enExample)
CA (1) CA2827809A1 (enExample)
CL (1) CL2013002622A1 (enExample)
CO (1) CO6801638A2 (enExample)
EA (1) EA201301109A1 (enExample)
EC (1) ECSP13012996A (enExample)
MA (1) MA35233B1 (enExample)
MX (1) MX337115B (enExample)
PE (1) PE20141157A1 (enExample)
PH (1) PH12013502031A1 (enExample)
SG (1) SG193557A1 (enExample)
TN (1) TN2013000389A1 (enExample)
TW (2) TWI535735B (enExample)
UY (1) UY33997A (enExample)
WO (1) WO2012131076A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2865464C (en) * 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Ang2-binding molecules
JP2015532272A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
MX2015003894A (es) * 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf.
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN110950967B (zh) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
KR20240048555A (ko) * 2021-09-10 2024-04-15 소테르 바이오파마 피티이. 리미티드 항 ang2 항체 및 그 제조방법과 응용
CN116444675B (zh) * 2023-05-11 2023-12-22 亲和(武汉)生命科技有限责任公司 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
WO2025111816A1 (en) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
NZ527591A (en) 2001-01-17 2006-04-28 Trubion Pharmaceuticals Inc Binding domain-immunoglobulin fusion proteins
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
CN103254309B (zh) * 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
DK1962895T3 (da) * 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
UA94464C2 (ru) * 2006-06-06 2011-05-10 Дженентек, Инк. Выделенное антитело к dll4 и его применение
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
US20080014196A1 (en) * 2006-06-06 2008-01-17 Genentech, Inc. Compositions and methods for modulating vascular development
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007293614A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2008234248C1 (en) * 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2011002837A (es) * 2008-09-19 2011-07-29 Medimmune Llc Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos.
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體

Also Published As

Publication number Publication date
NZ614243A (en) 2015-04-24
TW201302797A (zh) 2013-01-16
TN2013000389A1 (en) 2015-01-20
CA2827809A1 (en) 2012-10-04
EP2694545A1 (en) 2014-02-12
KR20140016345A (ko) 2014-02-07
EA201301109A1 (ru) 2014-08-29
US20130078247A1 (en) 2013-03-28
JP2014511682A (ja) 2014-05-19
PH12013502031A1 (en) 2013-12-16
UY33997A (es) 2012-09-28
WO2012131076A1 (en) 2012-10-04
ECSP13012996A (es) 2013-12-31
SG193557A1 (en) 2013-11-29
MA35233B1 (fr) 2014-07-03
BR112013025294A2 (pt) 2017-06-13
AP2013007086A0 (en) 2013-08-31
AU2012234218A1 (en) 2013-09-05
CN103596977A (zh) 2014-02-19
AR085919A1 (es) 2013-11-06
MX337115B (es) 2016-02-12
CN103596977B (zh) 2016-07-06
EP2694545B1 (en) 2016-08-24
TWI535735B (zh) 2016-06-01
MX2013011032A (es) 2013-12-06
CO6801638A2 (es) 2013-11-29
PE20141157A1 (es) 2014-09-24
TWI551612B (zh) 2016-10-01
CN106046167A (zh) 2016-10-26
TW201302789A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
CL2013002623A1 (es) Moleculas de union biespecificas que comprende al menos un componente que se une a vegf y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.
CL2013002622A1 (es) Moleculas de union biespecificas que comprende al menos un componente que se une a dll4 y ang2 y al menos un componente de union de albumina sérica; molecula de acido nucleico que codifica la molecula de union biespecifica; célula hospedera que comprende la molecula de acido nucleico; composicion farmaceutica que comprende dicha molecula.
BR112014000263A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
BR112013029893A2 (pt) molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
DK2723771T3 (da) Serumalbuminbindende proteiner
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2015001709A1 (es) Etiqueta de péptido que se une a hialuronano; ácido nucleico que la codifica; vector; célula hospedera; molécula etiquetada con dicho péptido; composición que la comprende; y método de producción de etiqueta de péptido.
EP2766382A4 (en) MEDITOPES AND MEDITO-BONDING ANTIBODIES AND THEIR USES
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
LTPA2018507I1 (lt) Daugiaspecifinė antigeną surišanti molekulė, turinti alternatyvią funkciją kraujo krešėjimo VIII faktoriaus funkcijai
CY1122978T1 (el) Αντισωματα εναντι-vla-4
EP2723379A4 (en) ANTI-ALPHA-SYNUCLEIN BINDING MOLECULES
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BRPI0821375B8 (pt) anticorpos biespecíficos, bivalentes, processo para a preparação destes e composição farmacêutica dos mesmos
EP2922566A4 (en) EGFR AND C-MET FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
CL2013001089A1 (es) Anticuerpos que se une especificamente a tnfalfa humano; composicion farmacéutica que la comprende; molécula de ácido nucleico aislado; vector; metodo para reducir la tendencia a la agregación de un anticuerpo.
ZA201209091B (en) Serum albumin binding molecules
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
EA201490768A1 (ru) Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
CL2014001123A1 (es) Anticuerpos anti-il 36r; composicion farmaceutica que lo contiene; polinucleotido aislado que codifica el anticuerpo; metodo para la produccion del anticuerpo; kit de diagnostico que lo contiene.
BR112014006881A2 (pt) composição para mistura de combustível, mistura de combustível e processo de produção à mistura de combustível
DK2185574T3 (da) Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met